

Genomic imbalances detected through array CGH in fetuses with holoprosencephaly

Isabela Nelly Machado, Juliana Karina Heinrich, Ricardo Barini

ABSTRACT

Objective: Holoprosencephaly (HPE) is heterogeneous in pathogenesis, integrating genetic susceptibility with the influence of environmental factors. Submicroscopic aberrations may contribute to the etiology of HPE. Our aim was to report the molecular analysis of 4 fetuses with HPE and normal metaphase karyotype. **Method:** A whole genome BAC-array based Comparative Genomic Hybridization (array CGH) was carried out in fetal blood samples. All potential cytogenetic alterations detected on the arrays were matched against the known copy number variations databases. **Results:** The array CGH analysis showed copy number gains and losses in all cases. We found a recurrent deletion in 15q14 (clone RP11-23J11) and in 15q22 (clone RP11-537k8) in 2 out of 4 cases analyzed. We also observed submicroscopic gain in 6p21 in 3 out of 4 fetuses in nearby clones. All these regions were tested in known databases and no copy number variations have been described for them. **Conclusion:** This is the first report of molecular characterization through a whole genome microarray CGH of fetuses with HPE. Our results may contribute to verify the effectiveness and applicability of the molecular technique of array CGH for prenatal diagnosis purposes, and contributing to the knowledge of the submicroscopic genomic instability characterization of HPE fetuses.

Key words: holoprosencephaly, comparative genomic hybridization, prenatal diagnosis, genetic testing, genomic instability.

Instabilidades genômicas detectadas através de array CGH em fetos com holoprosencefalia

RESUMO

Objetivo: Holoprosencefalia (HPE) é uma malformação heterogênea na patogênese, integrando a suscetibilidade genética com a influência de fatores ambientais. Aberrações submicroscópicas podem contribuir para a etiologia da HPE. Nosso objetivo foi relatar a análise molecular de 4 fetos com HPE e cariótipo normal. **Método:** Foi realizado um estudo descritivo prospectivo dos achados da técnica de hibridação genômica comparativa baseada em microarranjos utilizando BAC clones de ampla cobertura genômica (BAC-array CGH) em amostras sanguíneas de fetos portadores de holoprosencefalia e com cromossomos numericamente normais ao bandamento G. Todas as potenciais alterações citogenéticas detectadas foram comparadas com bancos de dados com variações do número de cópias conhecidas. **Resultados:** A análise de array CGH evidenciou ganhos e perdas do número de cópias em todos os 4 casos. Foram encontradas deleções recorrentes em 15q14 (clone RP11-23J11) e em 15q22 (clone RP11-537k8) em 2 dos 4 casos analisados. Observou-se em 3 fetos ganho genômico na região 6p21 em clones próximos. Todas estas regiões não apresentaram variações do número de cópias descritas em bancos de dados conhecidos. **Conclusão:** Este é o primeiro relato de caracterização molecular através de um microarray CGH de fetos com HPE. Nossos resultados podem contribuir para verificar a eficácia e aplicabilidade da técnica molecular de array CGH para fins de diagnóstico pré-natal, contribuindo para o conhecimento da caracterização de instabilidades genômicas submicroscópicas de fetos com HPE. **Palavras-chave:** holoprosencefalia, hibridização genômica comparativa, diagnóstico pré-natal, análise genética, instabilidade genômica.

Correspondence

Isabela Nelly Machado
Department of Obstetrics and Gynecology
Rua Alexander Fleming 101
13083-970 Campinas SP - Brasil
E-mail: imachado@fcm.unicamp.br

Support

This study was sponsored by
São Paulo State Research Foundation
FAPESP (Grant N° 2007/04684-0)

Received 25 November 2009
Received in final form 7 July 2010
Accepted 14 July 2010

Cell Culture and Cytogenetics Laboratory, Fetal Medicine Program of the Integral Assistance for Women's Health (CAISM) of the Department of Obstetrics and Gynecology. Faculty of Medical Sciences. State University of Campinas - UNICAMP, Campinas SP, Brazil.

Holoprosencephaly (HPE) OMIM 2361000, is the most common developmental defect of midline cleavage in human embryonic forebrain, with a variable phenotypic expression. Its estimated prevalence is of 1:16,000 live-births¹ and 1:250 conceptuses², but it should be higher considering the current advances in neuroimaging that allow the diagnosis of less severe forms of this malformation. The association of holoprosencephaly with other fetal structural and chromosomal abnormalities justifies a detailed investigation of the fetal morphology and karyotype.

Our current understanding of the pathogenesis of HPE attempts to integrate genetic susceptibility with the epigenetic influence of environmental factors. Identifiable genetic causes in humans account for about 15-20% of all cases³. The most common chromosomal abnormality associated to holoprosencephaly is the trisomy 13. To date, known human mutations in at least 12 different genetic loci have been associated with HPE⁴, but a very small percentage of all cases has a molecularly defined HPE. Therefore, submicroscopic aberrations may contribute to the etiology of HPE.

The aim of this study was to report the molecular findings through a whole genome array comparative genomic hybridization (array CGH) of 4 fetuses with prenatal ultra-sound diagnosis of HPE in an attempt to improve the knowledge of the submicroscopic abnormalities presented in these malformed fetuses.

METHOD

Patients and samples

For this study, fetuses with holoprosencephaly as an isolated brain malformation, no recognized genetic syndrome, and normal metaphase karyotype delivered between January 2008 and July 2009 were prospectively included. This study was carried out after the protocol approval by the institution's ethical committee.

The fetal and parental karyotype analysis was performed using G-banded metaphase chromosomes at approximately the 500 band level. All the parents gave informed consent. The presence and morphologic classification of HPE was confirmed by postnatal MRI (magnetic resonance imaging) or autopsy reports. Maternal diabetes mellitus, drug ingestion, exposure to alcohol and infections were excluded.

Fetal blood samples were collected by cordocentesis at different week's gestation for karyotype, according to the guidelines of the Fetal Medicine Unit of the Women's Hospital of the State University of Campinas (Unicamp).

Molecular study

Genomic DNA was extracted and purified from fetal blood by means of the Wizard® Genomic DNA Purifica-

tion Kit (Promega Corp., Madison, WI, USA), according to manufacturer's protocol for whole blood.

Array Comparative Genomic Hybridization was carried out using the Constitutional Chip® 4.0 (PerkinElmer Inc., Turku, Finland), comprised of approximately 5000 BAC (Bacterial Artificial Chromosome) clones, covering the whole human genome with an average resolution of <650 kb and spotted in duplicate.

For each experiment, a sex-mismatched normal reference DNA (Promega Corp., Madison, WI, USA) was used. The DNA concentrations used were 40 ng/μl. All experiments included dye reversal and two array hybridizations to obtain an accurate ratio. After post-hybridization washes, slides were scanned, and captured images were analyzed by either the GenePix® Pro 6.0 (Molecular Devices Corp.) or the ScanArray Express® (Microarray Analysis System 4.0.0.4) software.

After quantification, the cyanine 5 and cyanine 3 average ratio fluorescence intensities for each BAC clone on each of the duplicate arrays (gpr files) were uploaded into the web-based SpectralWare® v2.3.3 software (PerkinElmer Inc.), normalized with linear regression algorithms (on a log₂ scale) and plotted according to the BAC chromosomal location. The raw data from dye-reversed pairs were combined, and threshold values were ascertained to make inferences according to a clone-by-clone classification procedure to determine the gain, loss and no change status of each clone for each subject, relative to the diploid reference DNA. The threshold values were determined by the software using the "Iterative 2.5X Sigmas" algorithm. Subsequent normalization of the data with "Block Lowess" method was performed for verification of copy number changes. The P values for each probe were also calculated, furnishing additional objective statistical criteria to determine whether deviation of each probe from zero is a significant change⁵. The quality criteria adopted included standard deviation of the intensity ratios among the duplicates less than 10% and more than 97.5% of spots with adequate intensity ratio values for analysis⁶. For each analysis, all quality control metrics were noted to be optimal. Clone-by-clone changes were reviewed and only those aberrations detected in both hybridizations were studied further.

All potential cytogenetic alterations detected on the arrays were matched against the known online databases to determine whether they encompassed described copy number variations (CNV) regions.

RESULTS

Four unrelated fetuses were included in this study. There was no family history of congenital malformations or genetic disorders. Both women and their husbands were healthy, no consanguineous and presented normal

chromosomes at G-band analysis of peripheral blood. The maternal age ranged from 14 to 36 years old, with a parity varying from zero to two. One woman had previous spontaneous abortions, with no investigation for cytogenetics aberrations. The fetuses' hearts were morphologically normal at the fetal echocardiography. All the four babies were born alive with adequate weight for the gestational age and two of them, the semi-lobar and the alobar cases, died in the same day. An autopsy confirmed the prenatal findings and classification of HPE in all cases. The array CGH analysis showed copy number gains and losses in all cases.

Clinical aspects, the gestation outcome and the total number of clones with genomic instability observed in each case are summarized in Table 1.

We identified recurrent deletion in 15q14 and in

15q22 in 2 out of 4 cases analyzed. Based on the physical mapping positions as obtained from the March 2006 and February 2009 Assembly of the UCSC Genome Browser (<http://genome.ucsc.edu/>), the size of the deleted regions were determined to be 40,492 bp (37,806,124-37,846,615) and 174,345 bp (62,082,000-62,256,344), respectively. We also observed a recurrent copy number gain in 6p21 region in 3 out of 4 evaluated fetuses involving different but close clones (Figure). The complete list of abnormal clones found in the four fetuses is listed in Table 2. Details about the recurrent abnormal clones are listed in Table 3.

All the identified common regions were tested in known databases and four copy number variations (CNV) were found and excluded. They were gain at 1p36, 2q37.3 and 9q34, and loss at 5q13.

Table 1. Clinical aspects, gestation outcome and the total number of clones with genomic instability in 4 fetuses with holoprosencephaly.

Case	Maternal age*	GPA**	HPE	GA of cordocentesis	Karyotype	Abnormal clones***	GA of delivery	Outcome
#1	36	G3 P2 A0	Lobar	33	46,XX	20	36	Alive
#2	14	G1 P0 A0	Lobar	31	46,XY	17	39	Alive
#3	28	G2 P1 A0	Semi lobar	31	46,XY	22	41	Died in 1 hour
#4	28	G1 P0 A0	Alobar	27	46,XY	05	35	Died in 10 min.

GA: gestational age (weeks); *Maternal age (completed years); **G: gravidity, P: parity, A: number of abortions; ***Total number of abnormal clones.

Table 2. Abnormal clones detected in 4 fetuses with holoprosencephaly using whole genome array CGH.

#1		#2		#3		#4	
G	L	G	L	G	L	G	L
RP1-283E3	RP11-328L16	RP4-628J24	RP11-23J11	RP11-625N16	RP11-91G12	RP11-353K11	
RP1-160H23	RP3-375M21	RP1-77N19	RP11-537K8	RP11-118M12	RP11-352A18	RP5-1011O17	
RP11-602P21	RP11-173D3	RP5-856G1	RP11-300G13	RP3-462C17	RP11-551B22	RP11-15M20	
RP11-48C7		RP1-86C11		RP11-483F11	RP11-3G21	RP1-103M22	
RP1-44H16		RP3-428L16		GS-261-B16	RP11-107O19	RP11-80F22	
GS-908-H22		RP3-366N23		RP11-416K5	RP11-23J11		
RP5-908H22		RP11-173G21		RP11-160E2	RP11-537K8		
RP11-598F7		RP11-738I14		RP11-46E14			
RP11-277E18		RP11-91H5		GS-325-I23			
RP11-256C2		RP11-79M19		RP5-860F19			
RP11-26M6		RP11-142I8		RP11-379J5			
CTD-2184G2		RP11-103B5		RP4-745C22			
RP11-64L12		RP11-173D3		RP1-141I3			
RP11-67A5		RP1-81F12					
RP11-384E6							
RP11-17I20							
RP1-104C13							

L: Loss; G: Gain.

Table 3. Recurrent abnormal clones in 4 fetuses with holoprosencephaly.

Clone	Chromosome region	Size (bp)	Affected cases
RP11-23J11	15q14	40,492	#2, #3
RP11-537k8	15q22	174,345	#2, #3
RP3-462C17	6p21.1	118,106	#3
RP11-602P21	6p21.2	224,030	#1
RP1-86C11	6p21.3	89,016	#2

bp: base pairs.




Figure. Spectral view of chromosome 6 showing recurrent gain at 6p21.

DISCUSSION

HPE seems to be a multiple hit pathology, requiring two or more events involving several genes and/or environmental factors⁷. The pathology of HPE can be caused by environmental (drugs, infections) and metabolic (diabetes mellitus, alcohol, smoking) factors. Among genetic causes, it can be part of defined malformations syndromes with normal karyotype, chromosomal abnormalities as trisomy 13, trisomy 18 and triploidy, or it can be due to known sequence mutations on described chromosome regions.

The currently identified HPE genes only account for a small portion of all sporadic HPE cases (15-20%)³, and mutations in the currently recognized HPE genes explain only a very small proportion of all sporadic HPE cases⁸. In a cohort of 424 unrelated postnatal cases with severe central nervous system findings, normal karyotype and negative for the for four main HPE genes, micro deletions were found in 4.7% and no micro deletions were found in 85 individuals with HPE microsigns⁹. The same group of researchers found a percentage of 8.5% of microdeletions in the prenatal period in 97 fetuses¹⁰. The remaining

cases are assumed to be a non-known etiology manifestation: neither environmental, nor syndromic, nor chromosomal⁴. The difficulties in identifying these genes may relate to the multigenic nature of HPE. Loss of function in a single HPE gene may not lead to the disease. In human, there will be other modifier genes acting in addition¹¹. A recent study involving twenty members of an affected family showed the importance of perseverance despite initially negative tests, including applying new technology and testing newly discovered genes and highlighted the fact that genetic disorders may manifest in ways not exactly as traditionally described¹².

Therefore, we hypothesized that there are still unidentified genes causing underlying submicroscopic aberrations that could contribute to the etiology of HPE. In a first attempt to identify novel candidate regions involved in the pathology of this heterogeneous disease, and to evaluate the feasibility of BAC arrays in the analysis of prenatal samples, we used an array CGH pangenomic approach to report the molecular characterization of group of 4 fetuses with normal karyotype and diagnosis of HPE visible by ultra-sound prenatal care.

Table 4. Known genes and candidate genes for HPE.

LOCI and known HPE genes		Candidate genes	
236100	HPE1 21q22.3	Investigated or under investigation	
157170	HPE2 2p21 SIX3	600909	LSS 21q22,3 HPE1
142945	HPE3 7q36 SHH	605194	CFC1 2q21.1
142946	HPE4 18p11.3 TGIF	181590	SIL 1p32
609637	HPE5 13q32 ZIC2	605189	DKK1 10q11.2
605934	HPE6 2q37.1-q37.3	Hypothetical	
601309	HPE7 9q22.3 PTCH	602103	TMEM1 21q22.3
609408	HPE8 14q prox	600288	FOXA2 20p11
–	HPE9 20p13	607502	DISP1 1q42
–	HPE10 1q42-qter	609486	EAPP 14q13 HPE8
–	HPE11 5pter	609863	TECT1 12q24.1
–	HPE12 6q26-qter	603475	CHRD 3q27
600725	gene SHH 7q36	602991	NOG 17q22
602630	gene TGIF 18p11.3	600073	LPR2 2q24-q31
603073	gene ZIC2 13q32	601500	SMO 7q32.2
603714	gene SIX3 2p21	606178	HHIP 4q31.22
187395	gene TDGF1 3p23-p21	112262	BMP4 14q22.2
601309	gene PTCH 9q22	601265	NODAL 10q22.1
603621	gene FOXH1 8q24.3	601366	SMAD2/4 18q21
165230	gene GLI2 2q14	608707	CDO 11q23-q24
		605049	TWSG1 18p11.3

Dubourg et al.⁴, 2007.

The array CGH analysis showed copy number gains and losses in all cases. Interestingly, the alobar case, the more severely affected fetus, presented the smallest number of genomic abnormalities. Indeed, our results did not allow an inkling of correlation between the number and size of these imbalances and the severity of the phenotype.

The current described genes and candidate genes for HPE, with its respective chromosome regions are presented in Table 4⁴. It was not a goal of this study to search for mutations in the four main HPE genes (SHH, ZIC2, SIX3, TGIF), but we could observe that there were no abnormal clones in their known loci.

A Medline search using the keywords 15q14 and holoprosencephaly could not find any citation. The same occurred using the association between 15q22 or 6p21 and holoprosencephaly. One patient was related with a de novo reciprocal translocation affecting the breakpoints 6p21.1 and 7q36, presenting premaxillary agenesis (part of the HPE spectrum) as well as skeletal abnormalities and impacted teeth reminiscent of cleidocranial dysplasia (CCD). But, in this patient, the HPE phenotype could be explained by the 7q36 breakpoint that maps to the sonic hedgehog gene (SHH), the HPE3 described locus¹³. As the mutations in genes mapping the 6p21 region can

cause CCD, the breakpoint in this region in this case appears to explain the CCD phenotype¹⁴.

A possible association between the 15q22 region and holoprosencephaly could be postulated considering that, in some instances, the agenesis of corpus callosum can be part of the holoprosencephaly spectrum³. Of the clinical manifestations reported cases of individuals with deletions encompassing 15q15-q22 region, one patient showed partial agenesis of corpus callosum¹⁵ and other showed hypoplastic corpus callosum¹⁶.

The inheritance background of our findings is unknown as blood samples from the parents were not available for array CGH analysis to determine if the copy number gains were inherited or de novo.

The greatest care must be taken for molecular prenatal diagnosis in HPE. Even if a mutation has been identified and seems to be transmitted with clinical manifestations in the family, another event, like a mutation in another gene (not yet identified) or an environmental factor, may be necessary to generate the holoprosencephaly phenotype⁷. In this case, molecular biology performed prenatally provides only an additional criterion with regard to prenatal ultrasound or MRI, which still takes precedence over molecular analysis.

Microarray-based CGH is a powerful method to detect and analyze genomic imbalances that are well below the level of detection on high resolution banded karyotype analysis providing a better opportunity for genotype/phenotype correlations in other similarly affected individuals. Array CGH is relatively widely used in genetic testing of children. Recently, a case with the middle interhemispheric variant, a milder variant of HPE, was described carrying a deletion of ~10.4 Mb at 6q22.31-q23.2, suggesting a novel candidate gene of HPE¹⁷. But its true potential is still under-explored in prenatal diagnosis.

Some advantages of this molecular method is that it does not involve cell culture, does not require prior knowledge of the genomic region involved and the ability to study cases where only DNA is available and no chromosomes can be obtained. The method was reproducible in a clinical standpoint, with reliable results within 48 hours. Thus, we demonstrate that the technique of array CGH can become an excellent tool for prenatal diagnosis. But, it is important to emphasize that array CGH may not replace conventional G-banded karyotype analysis, but it can complement and expand current methods for a precise prenatal diagnosis and syndromes' characterization. One advantage of G banding analysis is that it allows the detection of somatic chromosomal mosaicism, which has been described in some patients with PHE.

Based on our results, array CGH results are promising in prenatal genetic testing and a study for submicroscopic deletions in fetuses with non-syndromic HPE should be

considered as part of the routine laboratory evaluation, in addition to high resolution chromosomal and mutation analysis. Positive results in any of these studies will help to better understand the etiology of HPE and aid the establishment of the recurrence risk for family counseling. Moreover, additional research is needed to further establish the role of genes from related chromosome regions in brain development and to determine the prevalence of copy number gain in the 15q and 6p regions among HPE patients. Also, in accordance with others authors, epidemiologic investigations should be conducted to check off environmental factors that could act in coordination with genetic events to give rise to holoprosencephaly.

ACKNOWLEDGMENTS – The authors have no conflict of interest with any of the information presented in this article. We are grateful to the families who participate in this research. We thank members of the Cell Culture and Cytogenetics Laboratory of the Women's Hospital (CAISM – State University of Campinas – UNICAMP) for their contribution throughout the course of this project and Christopher Williams (PerkinElmer Inc., Waltham, MA) for skilled technical assistance. Electronic-Database and online software: The URL for data presented herein is as follows: SpectralWare® v2.3.3 software (PerkinElmer Inc.), <http://service.spectralgenomics.com> (for the array analysis). Database of Genomics Variants, <http://projects.tcag.ca/variation/> (for CNV search). Copy Number Variation, <http://cnv.chop.edu/> (for CNV search). UCSC Genome Browser, <http://genome.ucsc.edu/>. (for physical mapping positions and size determination of chromosomal regions). Medline, <http://www.ncbi.nlm.nih.gov/pubmed/>. (for literature search).

REFERENCES

1. Rasmussen S, Moore C, Khoury M, Cordero J. Descriptive epidemiology of holoprosencephaly and arhinencephaly in metropolitan Atlanta, 1968-1992. *Am J Med Genet* 1996;66:320-333.

2. Matsunaga E, Shiota K. Holoprosencephaly in human embryos: epidemiologic studies of 150 cases. *Teratology* 1977;16:261-272.
3. Cohen MJ. Holoprosencephaly: clinical, anatomic, and molecular dimensions. *Birth Defects Res A Clin Mol Teratol* 2006;76:658-673.
4. Dubourg C, Bendavid C, Pasquier L, Henry C, Odent S, David V. Holoprosencephaly. *Orphanet J Rare Dis* 2007;2:8.
5. Ng G, Huang J, Roberts I, Coleman N. Defining ploidy-specific thresholds in array comparative genomic hybridization to improve the sensitivity of detection of single copy alterations in cell lines. *J Mol Diagn* 2006;8:449-458.
6. Vermeesch J, Melotte C, Froyen G, et al. Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. *J Histochem Cytochem* 2005;53:413-422.
7. Ming J, Muenke M. Multiple hits during early embryonic development: digenic diseases and holoprosencephaly. *Am J Hum Genet* 2002;71:1017-1032.
8. Nanni L, Croen L, Lammer E, Muenke M. Holoprosencephaly: molecular study of a California population. *Am J Med Genet* 2000;90:315-319.
9. Bendavid C, Haddad B, Griffin A, et al. Multicolour FISH and quantitative PCR can detect submicroscopic deletions in holoprosencephaly patients with a normal karyotype. *J Med Genet* 2006;43:496-500.
10. Bendavid C, Dubourg C, Gicquel I, et al. Molecular evaluation of fetuses with holoprosencephaly shows high incidence of microdeletions in the HPE genes. *Hum Genet* 2006;119:1-8.
11. Shen J, Walsh C. Targeted disruption of Tgif, the mouse ortholog of a human holoprosencephaly gene, does not result in holoprosencephaly in mice. *Mol Cell Biol* 2005;25:3639-3647.
12. Solomon BD, Lacbawan F, Jain M, et al. A novel SIX3 mutation segregates with holoprosencephaly in a large family. *Am J Med Genet Part A* 2009;149:919-925.
13. Huang J, Hoffman JD, Zhang Y, et al. Identification of a submicroscopic deletion of SHH associated with the holoprosencephaly spectrum by array-based CGH. *Clin Genet* 2006;69:367-369.
14. Fernandez B, Siegel-Bartelt J, Herbrick J, Teshima I, Scherer S. Holoprosencephaly and cleidocranial dysplasia in a patient due to two position-effect mutations: case report and review of the literature. *Clin Genet* 2005;68:349-359.
15. Lalani S, Sahoo T, Sanders M, Peters S, Bejjani B. Coarctation of the aorta and mild to moderate developmental delay in a child with a de novo deletion of chromosome 15(q21.1q22.2). *BMC Med Genet* 2006;7:8.
16. Koivisto P, Koivisto H, Haapala K, Simola K. A de novo deletion of chromosome 15(q15.2q21.2) in a dysmorphic, mentally retarded child with congenital scalp defect. *Clin Dysmorphol* 1999;8:139-141.
17. Abe Y, Oka A, Mizuguchi M, et al. EYA4, Deleted in a case with middle interhemispheric variant of holoprosencephaly, interacts with SIX3 both physically and functionally. *Hum Mutat* 2009;30:946-955.